Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.